Sign in
Taking people in United StatesPhase 2

Tests tirzepatide against placebo in people with obesity and atrial fibrillation

Tests tirzepatide, compared with placebo, in adults with obesity and atrial fibrillation.

Key facts

Who runs it
The Cleveland Clinic
Where
Cleveland, United StatesSee the site
Trial code
Registry title
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
8 Apr 2025
Expected to end
1 Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tirzepatide
  • Placebo
Record updated
13 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity and symptomatic atrial fibrillation who are in normal heart rhythm at the start. Half get tirzepatide and half get a placebo.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Symptomatic atrial fibrillation, either paroxysmal or persistent, documented by ECG or monitor. BMI from 27 to 60 kg/m2. Normal sinus rhythm at randomization.
Earlier treatment
Diabetes medicines, including insulin, must be stable for at least 3 months. No use of GLP-1/DPP4i or GIP/GLP-1 medicines in the last 6 months. No ablation for AFIB in the last 6 months.
Biomarker or test result
HbA1c 10% (86 mmol/mol) or lower for people with type 2 diabetes.

Main reasons for not taking part

  • NYHA class III or IV heart failure, or left ventricular ejection fraction below 35%
  • Type 1 diabetes or autoimmune diabetes
  • Personal or family history of pancreatitis, medullary thyroid cancer or MEN2
  • Pregnant, breast-feeding or planning pregnancy
  • eGFR below 30 mL/min/1.73 m2 or on dialysis

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Subjects eligible for inclusion in this study must meet all of the following criteria:
  • Sinus rhythm at randomization; Sustained normal sinus rhythm (or); Normal sinus rhythm at office visit
  • Age ≥18 to ≤80 years old
  • BMI ≥ 27 and ≤60 kg/m2
  • AFIB criteria:; Must be documented by ECG or monitor; Must have symptomatic AFIB (Atrial Fibrillation); In terms of types of AFIB, either paroxysmal AFIB or persistent AFIB
  • All anti-diabetic medication (including insulin) must be stable for at least 3 months prior to enrollment,
  • HbA1c ≤10% for patients diagnosed with Type 2 Diabetes Mellitus (T2DM)
  • Ability and willingness to give themselves the medication, comply with study requirements and provide written informed consent

Who cannot take part

  • Planned ablation prior to 3 months post randomization
  • Current participation or use of investigational therapy or less than 3 months since participation in any drug or device trial
  • Life expectancy less than 3 years due to concomitant diseases
  • Current use or any use within the last 6 months of GLP-1/DPP4i (Glucagon-Like Peptide-1/Dipeptidyl Peptidase-4 inhibitor) or GIP (Gastric Inhibitory Polypeptide)/GLP-1
  • Known hypersensitivity to investigational product due to prior use of GLP-1/DPP4i or GIP/GLP-1
  • Significant cardiac valvular disease with planned cardiac valve intervention/surgery in the next 12 months
  • Severe uncompensated cardiopulmonary disease
  • New York Heart Association Class III or IV
  • Hospitalization in the past 6 months for myocardial infarction, unstable angina, stroke, transient ischemic attack, or heart surgery
  • History of solid organ transplant
  • Type 1 diabetes mellitus or auto-immune diabetes
  • Advanced and decompensated cirrhosis characterized by: presence of fibrosis stage 4 (cirrhosis) in liver biopsy, ascites, hepatic encephalopathy, portal hypertension, or esophageal varices
  • Presence of active malignancy (except non-melanoma skin cancer)
  • Major mental health, psychological disorders, or substance abuse disorders that could disqualify the patient from metabolic surgery
  • Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study
  • Any personal or family history of pancreatitis or medullary thyroid cancer or MEN2 (Multiple Endocrine Neoplasia Type 2)
  • Allergy to medical grade tape or adhesive
  • Left ventricular ejection fraction <35% at the time of screening
  • Estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m2 at screening or on dialysis
  • Hemoglobin less than 9 g/dL
  • Liver transaminase level >300 U/L
  • Subjects meeting any of the following criteria are not eligible for inclusion in this study
  • AFIB ablation within the last 6 months
  • Subject reports alcohol use of on average >2 drinks/day
  • Plans to move outside the primary location of study (Northeast Ohio) within the next 12 months
  • Pregnant, breast-feeding or plans to become pregnant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Cleveland ClinicCleveland, United StatesContact: Jeannine Ramsey, RN, BSNTaking people

About the trial

What the trial wants to find out

This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.

The 2 groups in the trial

  • TirzepatideTreatment being tested

    Participants to inject weekly subcutaneous injections of Tirzepatide starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg) as tolerated.

  • ControlPlacebo, for comparison

    Participants to inject weekly subcutaneous injections of normal saline starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
TIRO-AF: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Plain-language title
Tests tirzepatide against placebo in people with obesity and atrial fibrillationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06802081, who can take part
Record updated
13 January 2026